Oracle Agile PLM 9.3.6 Gantt Chart privileges management
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.1 | $5k-$25k | 0.40- |
Summary
A vulnerability classified as problematic has been found in Oracle Agile PLM 9.3.6. Affected by this issue is some unknown functionality of the component Gantt Chart. The manipulation leads to privileges management. This vulnerability is referenced as CVE-2026-71041. The attack can only be performed from a local environment. No exploit is available.
Details
A vulnerability, which was classified as problematic, has been found in Oracle Agile PLM 9.3.6. This issue affects some unknown processing of the component Gantt Chart. The manipulation with an unknown input leads to a privileges management vulnerability. Using CWE to declare the problem leads to CWE-269. The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor. Impacted is confidentiality, integrity, and availability. The summary by CVE is:
Vulnerability in the Oracle Agile PLM product of Oracle Supply Chain (component: Gantt Chart). The supported version that is affected is 9.3.6. Difficult to exploit vulnerability allows low privileged attacker with logon to the infrastructure where Oracle Agile PLM executes to compromise Oracle Agile PLM. Successful attacks of this vulnerability can result in takeover of Oracle Agile PLM. CVSS 3.1 Base Score 7.0 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:H).
It is possible to read the advisory at oracle.com. The identification of this vulnerability is CVE-2026-71041 since 08/05/2026. The exploitation is known to be easy. Attacking locally is a requirement. The technical details are unknown and an exploit is not publicly available. The pricing for an exploit might be around USD $5k-$25k at the moment (estimation calculated on 08/19/2026). The attack technique deployed by this issue is T1068 according to MITRE ATT&CK.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.
Product
Type
Vendor
Name
Version
License
Website
- Vendor: https://www.oracle.com
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 6.1VulDB Meta Temp Score: 6.1
VulDB Base Score: 5.3
VulDB Temp Score: 5.3
VulDB Vector: 🔒
VulDB Reliability: 🔍
CNA Base Score: 7.0
CNA Vector (oracle): 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Privileges managementCWE: CWE-269 / CWE-266
CAPEC: 🔒
ATT&CK: 🔒
Physical: Partially
Local: Yes
Remote: No
Availability: 🔒
Status: Not defined
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
08/05/2026 CVE reserved08/18/2026 VulDB entry created
08/19/2026 Advisory disclosed
08/19/2026 VulDB entry last update
Sources
Vendor: oracle.comAdvisory: oracle.com
Status: Confirmed
CVE: CVE-2026-71041 (🔒)
GCVE (CVE): GCVE-0-2026-71041
GCVE (VulDB): GCVE-100-392195
Entry
Created: 08/19/2026 01:39Changes: 08/19/2026 01:39 (62)
Complete: 🔍
Cache ID: 216::103
Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.